Merck
CN
  • Design and Synthesis of 4-Anilinothieno[2,3-d]pyrimidine-Based Compounds as Dual EGFR/HER-2 Inhibitors.

Design and Synthesis of 4-Anilinothieno[2,3-d]pyrimidine-Based Compounds as Dual EGFR/HER-2 Inhibitors.

Archiv der Pharmazie (2016-11-03)
Soha R Abd El Hadi, Deena S Lasheen, Mahmoud A Hassan, Khaled A M Abouzid
ABSTRACT

Dual inhibition of the epidermal growth factor receptor (EGFR) and the human epidermal growth factor receptor 2 (HER-2) is an attractive cancer therapeutic approach. In this study, new series of 4-anilinothieno[2,3-d]pyrimidines were designed, synthesized, and tested as dual EGFR/HER-2 kinase inhibitors. Five compounds (8a, 8b, 8e-g) demonstrated low to submicromolar inhibition of both kinases with IC

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Poly(Glu, Tyr) sodium salt, Glu:Tyr (4:1), mol wt 5,000-20,000